Zinc finger protein 384 (ZNF384) impact on childhood mixed phenotype acute leukemia and B-cell precursor acute lymphoblastic leukemia
| العنوان: | Zinc finger protein 384 (ZNF384) impact on childhood mixed phenotype acute leukemia and B-cell precursor acute lymphoblastic leukemia |
|---|---|
| المؤلفون: | Tugce Sudutan, Yucel Erbilgin, Ozden Hatirnaz Ng, Serap Karaman, Zeynep Karakas, Fulya Kucukcankurt, Tiraje Celkan, Cetin Timur, Gul Nihal Ozdemir, Sadan Hacısalihoglu, Sema Aylan Gelen, Müge Sayitoğlu |
| المساهمون: | İstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Tülin Tiraje Celkan / 0000-0001-7287-1276, Gül Nihal Özdemir / 0000-0002-3204-4353, Celkan, Tülin Tiraje, Özdemir, Gül Nihal, Tülin Tiraje Celkan / FZB-3980-2022, Gül Nihal Özdemir / AAO-9962-2020, Tülin Tiraje Celkan / 35584411200, Gül Nihal Özdemir / 57208780173, Acibadem University Dspace |
| المصدر: | Leukemia & Lymphoma. 63:2931-2939 |
| بيانات النشر: | Informa UK Limited, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Cancer Research, Oncology, B-Cell Precursor ALL, Mixed Phenotype Acute Leukemia, ZNF384 Expression Levels, Hematology, ZNF384 Fusion |
| الوصف: | B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a heterogeneous malignancy and consists of several genetic abnormalities. Some of these abnormalities are used in clinics for risk calculation and treatment decisions. Patients with ZNF384 rearrangements had a distinct expression profile regardless of their diagnosis, BCP-ALL or mixed phenotype acute leukemia (MPAL) and defined as a new subtype of ALL. In this study, we screened 42 MPAL and 91 BCP-ALL patients for the most common ZNF384 fusions; ZNF384::TCF3, ZNF384::EP300 and ZNF384::TAF15 by using PCR. We identified ZNF384 fusions in 9.5% of MPAL and 7.6% of BCP-ALL. A novel breakpoint was identified in ZNF384::TCF3 fusion in one BCP-ALL patient. T-myeloid MPAL patients showed significantly lower ZNF384 expression compared to lymphoid groups. Patients with ZNF384r had intermediate survival rates based on other subtypes. Prognostic and patient-specific treatment evaluation of ZNF384 fusions in both ALL and MPAL might help to improve risk characterization of patients. 35921545 |
| وصف الملف: | application/pdf |
| تدمد: | 1029-2403 1042-8194 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0174848ed8c1d9c76e369be542b1a1aaTest https://doi.org/10.1080/10428194.2022.2095630Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....0174848ed8c1d9c76e369be542b1a1aa |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10292403 10428194 |
|---|